Monkeypox (Mpox) Vaccine

Get text updates about mpox from the County. Text COSD MONKEYPOX to 468-311. (Phone users: tap to create the message)

• Mpox Vaccine Eligibility
• Vaccine-Related Frequently Asked Questions
• What You Need to Know
• Vaccination Schedule and Dosing Regimens for Jynneos Vaccine
• Cumulative Vaccine Summary
  
• Mpox (Jynneos) Vaccine Vial Allocation by Phase
  
• Mpox Vaccination Summary

Mpox VACCINE ELIGIBILITY

While there is currently adequate vaccine supply, vaccine providers can offer vaccine to any patients who may be at risk, and persons who request vaccination should receive it without having to attest to specific risk factors.

The following is a list of County-coordinated vaccination sites. Please visit the Mpox Vaccinations Schedule webpage for more information.

• East Public Health Center (El Cajon)* 
  • 367 N. Magnolia Ave, 92020 
• North Central Public Health Center (San Diego)* 
  • 5055 Ruffin Rd., 92123
• North Coastal Live Well Health Center (Oceanside)* 
  • 1701 Mission Ave., Oceanside, CA 92058 
• North Inland Public Health Center (Escondido)* 
  • 649 W. Mission Ave, 92025 

* Point of Dispensing (POD) County Regional Sites

 VACCINE-RELATED FREQUENTLY ASKED QUESTIONS

WHAT YOU NEED TO KNOW

• JYNNEOS vaccine is approved for the prevention of mpox and smallpox disease.
• The standard regimen for JYNNEOS involves a subcutaneous (SQ) route of administration with an injection volume of 0.5mL. In the context of the current national Public Health Emergency (PHE), an alternative regimen involving intradermal (ID) administration with an injection volume of 0.1mL may be used under an Emergency Use Authorization (EUA).
• People can be vaccinated after exposure to mpox virus to help prevent mpox disease (i.e., post-exposure prophylaxis).
• No data are currently available on the clinical efficacy or effectiveness of JYNNEOS vaccines in the current outbreak.
• Because there are limitations in our knowledge about the effectiveness of these vaccines in the current outbreak, people who are vaccinated should continue to take steps to protect themselves from infection by avoiding close, skin-to-skin contact, including intimate contact, with someone who has mpox.
• Globally and in the United States, supply of JYNNEOS vaccine is currently limited, although more is expected in the coming weeks and months. In the United States, there is a large supply of ACAM2000, but this vaccine has more side effects and contraindications. Hence, it will not be used by the Centers for Disease Control and Prevention (CDC). 
• For more information:
  • JYNNEOS Vaccine Information Statement
  • JYNNEOS Fact Sheet for Healthcare Providers Administering Vaccine 
  • JYNNEOS Emergency Use Authorization (EUA) Fact Sheet for Patients and Caregivers | Spanish

VACCINATION SCHEDULE AND DOSING REGIMENS FOR JYNNEOS VACCINE¹

¹ cdc.gov/poxvirus/monkeypox/interim-considerations/jynneos-vaccine.html

Top of Page

VACCINE ALLOCATION SUMMARY

Note: Effective 1/12/23, the Cumulative Vaccine Summary and Vial Allocation by Phase are no longer being updated as providers directly may order vaccines from myCAvax.

• View the latest Cumulative Vaccine Summary with data through January 9, 2023.
• View the latest Mpox (Jynneos) Vaccine Vial Allocation by Phase report, with data through January 10, 2023.

Mpox Vaccination Summary

Data are preliminary and subject to change

Note: Effective 1/10/2023, Mpox vaccine total and demographic graph will be updated on the first Tuesday of each month.

Jynneos Vaccination Report PDF

Data as of: January 9, 2023
Updated: January 10, 2023

For more information, contact the Epidemiology Unit at (619) 692-8499 or send us an e-mail.

Top of Page